56309-60-5

Usage

Uses

Used in the Coatings Industry:
2-(TERT-BUTYL)PHENYL ISOCYANATE is used as a key component in the production of polyurethane coatings for its ability to contribute to the formation of durable and high-performance coatings with desirable properties such as hardness, flexibility, and resistance to various environmental factors.
Used in the Adhesives Industry:
In the adhesives industry, 2-(TERT-BUTYL)PHENYL ISOCYANATE is used as a reactive monomer to formulate polyurethane adhesives, which are known for their strong bonding capabilities, resistance to wear and tear, and adaptability to various substrates. This makes them suitable for a wide range of applications, including automotive, construction, and packaging sectors.

InChI:InChI=1/C11H13NO/c1-11(2,3)9-6-4-5-7-10(9)12-8-13/h4-7H,1-3H3

Upstream product

• 75-44-5 phosgene 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 903680-71-7 1-(2-tert-butylphenyl)-3-(2-ethylphenyl)urea 
• 959558-33-9 1,3-bis(2-tert-butylphenyl)urea 
• 1202526-41-7 1-(2-tert-butylphenyl)-3-(2-hydroxy-4-nitrophenyl)urea 
• 1316193-92-6 3-methyl-1-(2-tert-butylphenyl)-5-methyleneimidazolidine-2,4-dione 
• 1316854-76-8 6-(2-tert-butylphenyl)-8-methyl-3-phenyl-1-oxa-2,6,8-triazaspiro[4.4]non-2-ene-7,9-dione 
• 1383532-86-2 3-(2-(tert-butyl)phenyl)-5,5-dimethyl-4-methyleneoxazolidin-2-one 
• 1383532-82-8 2-methylbut-3-yn-2-yl (2-t-butylphenyl)carbamate 

Relevant academic research and scientific papers

Carbene-Catalyzed Atroposelective Annulation and Desymmetrization of Urazoles

An NHC-catalyzed atroposelective reaction between ynals and urazoles is disclosed. The reaction establishes a chiral C-N axis via an atroposelective [3 + 2] annulation/desymmetrization process. Our reaction allows efficient access to axially chiral and heteroatom-rich urazole derivatives with potential applications in bioactive molecules and catalysis.

SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME

The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Urazole chiral axis compound and catalytic asymmetric synthesis method thereof

The invention discloses an urazole chiral axis compound. The urazole chiral axis compound is represented by a formula I or II, wherein the R is selected from alkyl, halogen, phenyl, substituted phenyl and other groups shown in the descriptions, the R is selected from halogen, alkyl and alkoxy, the R and the R are respectively and independently selected from an aliphatic substituent group and an aromatic substituent group, and the R, R, R and R are respectively and independently selected from hydrogen, halogen, phenyl, substituted phenyl, alkyl, alkoxy, hydroxyl, a ester group, an aldehyde group, a cyano group and amide. The R represents an aryl group free of a substituent group or provided with one or more of substituent groups, and the R' represents hydrogen or alkyl. The invention further discloses an asymmetric synthesis method of the compound. The high-yield high-ee-value urazole chiral axis compound is prepared through synthesis under the moderate reaction conditions. The synthesis method has very good substrate adaptability and can achieve synthesis of more than shown grams of the compound under the situation that the dosage of a catalyst is decreased. The compound can serve as a catalyst or a ligand for a certain asymmetric reactions.

Structural optimization of a CXCR2-directed antagonist that indirectly inhibits γ-secretase and reduces Aβ

Amyloid β (Aβ), a key molecule in the pathogenesis of Alzheimer's disease (AD), is derived from the amyloid precursor protein (APP) by sequential proteolysis via β- and γ-secretases. Because of their role in generation of Aβ, these enzymes have emerged as important therapeutic targets for AD. In the case of γ-secretase, progress has been made towards designing potent inhibitors with suitable pharmacological profiles. Direct γ-secretase inhibitors are being evaluated in clinical trials and new strategies are being explored to block γ-secretase activity indirectly as well. In this regard, we have previously reported an indirect regulation of γ-secretase through antagonism of CXCR2, a G-protein coupled receptor (GPCR). We demonstrated that N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea (SB225002), a selective inhibitor of CXCR2 also plays a role in an indirect inhibition of γ-secretase. Furthermore, we reported a ～5-fold difference in the selective inhibition of APP versus Notch processing via γ-secretase following treatment with SB225002. Herein we describe the synthesis and optimization of SB225002. By determination of the structure-activity relationship (SAR), we derived small molecules that inhibit Aβ40 production with IC50 values in the sub-micromolar range in a cell-based assay and also validated the potential of CXCR2 as a new target for therapeutic intervention in AD.